ICCC IMMUCELL CORP /DE/
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 811641 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.6%
TTM net income YoY-19.1%
TTM EPS YoY-32.1%
Revenue 3-yr CAGR26.8%
Net income 3-yr CAGR—
Margins
Gross margin40.8%
Operating margin14.5%
Net margin5.7%
FCF margin16.3%
EBITDA margin21.0%
Returns
ROE6.0%
ROA4.2%
ROIC (approx.)13.8%
Asset turnover0.73x
Leverage & solvency
Liabilities / assets31.7%
Debt / equity0.24x
Current ratio4.61x
Interest coverage12.19x
Cash quality & payout
Operating cash flow / net income4.17x
Accruals ratio-13.2%
Payout ratio—
Capex / revenue7.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $27.64M | $26.49M | $17.47M | $18.57M | $19.24M |
| Cost of revenue | $16.20M | $18.55M | $13.60M | $10.92M | $10.59M |
| Gross profit | $11.45M | $7.94M | $3.87M | $7.65M | $8.66M |
| R&D expense | $3.04M | $3.90M | $4.39M | $4.49M | $4.17M |
| SG&A expense | $3.20M | $2.22M | $2.13M | $2.26M | $1.73M |
| Operating income | $1.65M | -$1.64M | -$5.75M | -$2.30M | $257,385 |
| Interest expense | $493,384 | $568,725 | $475,598 | $348,536 | $314,359 |
| Pretax income | -$1.03M | -$2.15M | -$5.77M | -$2.49M | -$69,127 |
| Income tax | $11,570 | $10,056 | $4,627 | $7,672 | $9,165 |
| Net income | -$1.04M | -$2.16M | -$5.77M | -$2.49M | -$78,292 |
| EBITDA | $4.43M | $1.09M | -$3.05M | $169,536 | $2.70M |
| EPS (basic) | -0.12 | -0.26 | -0.75 | -0.32 | -0.01 |
| EPS (diluted) | -0.12 | -0.26 | -0.75 | -0.32 | -0.01 |
| Weighted avg. shares (diluted) | 9.03M | 8.17M | 7.75M | 7.75M | 7.59M |
| Balance sheet | |||||
| Cash & equivalents | $3.81M | $3.76M | $978,741 | $5.79M | $10.19M |
| Receivables | $3.42M | $3.77M | $2.19M | $1.76M | $2.69M |
| Inventory | $9.27M | $7.11M | $7.81M | $6.04M | $3.09M |
| Current assets | $16.94M | $15.04M | $11.47M | $13.99M | $16.26M |
| PP&E, net | $21.07M | $25.35M | $27.58M | $28.44M | $26.89M |
| Goodwill | $95,557 | $95,557 | $95,557 | $95,557 | $95,557 |
| Intangibles | $0 | $19,104 | $38,208 | $57,312 | $76,416 |
| Total assets | $42.53M | $45.10M | $43.81M | $44.86M | $44.47M |
| Current liabilities | $3.98M | $4.41M | $4.20M | $3.07M | $2.53M |
| Short-term debt | $1.61M | $1.50M | $1.43M | $8.90M | — |
| Long-term debt | $7.49M | $9.04M | $10.54M | $9.19M | $812,207 |
| Total debt | $9.10M | $10.54M | $11.97M | $18.09M | $812,207 |
| Total liabilities | $15.48M | $17.58M | $18.82M | $14.48M | $11.89M |
| Shareholders' equity | $27.06M | $27.52M | $24.99M | $30.38M | $32.58M |
| Net debt | $5.29M | $6.78M | $10.99M | $12.30M | -$9.37M |
| Shares outstanding | 9.05M | 8.98M | 7.75M | 7.75M | 7.74M |
| Cash flow statement | |||||
| Operating cash flow | $2.48M | $357,903 | -$4.67M | -$1.54M | $954,170 |
| Capital expenditure | $1.25M | $465,725 | $1.89M | $3.98M | $2.61M |
| Free cash flow | $1.22M | -$107,822 | -$6.57M | -$5.52M | -$1.65M |
| Investing cash flow | -$1.21M | -$461,225 | -$1.89M | -$3.96M | -$1.60M |
| Financing cash flow | -$1.21M | $2.88M | $1.75M | $1.11M | $3.88M |
| Depreciation & amortization | $2.78M | $2.73M | $2.70M | $2.47M | $2.44M |
| Stock-based compensation | $295,871 | $325,551 | $368,866 | $266,244 | $144,313 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.